SO
| |
SR ONE CAPITAL MANAGEMENT, LP13F | |
| SR ONE CAPITAL MANAGEMENT, LP | |
| Last update 2025-05-13 | 12 Stocks (1 new) |
| Value $389.00 Mil | Turnover 6 % |
SR ONE CAPITAL MANAGEMENT, LP Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACLX | Arcellx Inc | 2,346,630 | 153,938.9 | 0% | 39.540 | 0% | 4.260 | +7.56% | -12.43% | 3,701.0 | Biotechnology | |
SPRY | ARS Pharmaceuticals Inc | 4,012,903 | 50,482.3 | 0% | 12.970 | 0% | 4.090 | +23.28% | +56.59% | 1,622.5 | Biotechnology | |
MLYS | Mineralys Therapeutics Inc | 3,127,933 | 49,671.6 | +55.09% | 12.760 | +4.53% | 4.820 | +7.46% | +18.12% | 947.6 | Biotechnology | |
ZBIO | Zenas BioPharma Inc | 4,911,539 | 38,801.2 | 0% | 9.970 | 0% | 11.740 | +28.59% | +22.47% | 419.6 | Biotechnology | |
CRSP | CRISPR Therapeutics AG | 1,048,951 | 35,695.8 | 0% | 9.170 | 0% | 1.210 | +59.74% | +32.55% | 4,505.6 | Biotechnology | |
DSGN | Design Therapeutics Inc | 6,526,476 | 25,192.2 | 0% | 6.470 | 0% | 11.500 | +7.10% | -38.90% | 214.0 | Biotechnology | |
ALMS | Alumis Inc | 1,959,896 | 12,033.8 | 0% | 3.090 | 0% | 3.600 | -60.19% | -56.74% | 350.8 | Biotechnology | |
OCS | Oculis Holding AG | 322,500 | 6,137.2 | New Holding | 1.580 | +1.58% | 0.620 | +8.02% | +11.76% | 969.6 | Biotechnology | |
NKTX | Nkarta Inc | 3,333,333 | 6,133.3 | 0% | 1.580 | 0% | 4.700 | +2.64% | -29.72% | 124.2 | Biotechnology | |
ORKA | Oruka Therapeutics Inc | 430,330 | 4,415.2 | 0% | 1.130 | 0% | 1.150 | +41.26% | -35.02% | 471.8 | Biotechnology |
SR ONE CAPITAL MANAGEMENT, LP's Historical Top Holdings Breakdowns
SR ONE CAPITAL MANAGEMENT, LP's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
MLYS | Mineralys Therapeutics Inc | 2025-03-31 | Add Add | +4.53% | 8.76 ($11.5) 16.87 | $14.54 | 26.43% | Add 55.09% | 3,127,933 | 1,111,111 | |
OCS | Oculis Holding AG | 2025-03-31 | New Buy New Buy | +1.58% | 16.93 ($20.5) 22.91 | $19.00 | -7.32% | New holding | 322,500 | 322,500 | |
KALA | Kala Bio Inc | 2024-12-31 | Add Add | +0.26% | 5.11 ($6.32) 7.63 | $5.10 | -19.30% | Add 35% | 598,940 | 155,279 | |
ORKA | Oruka Therapeutics Inc | 2024-12-31 | Add Add | +0.26% | 18.51 ($24.39) 30.49 | $12.60 | -48.34% | Add 14.65% | 430,330 | 55,000 | |
ZBIO | Zenas BioPharma Inc | 2024-09-30 | New Buy New Buy | +16.66% | 16.92 ($17.98) 19.23 | $10.03 | -44.22% | New holding | 4,911,539 | 4,911,539 | |
ORKA | Oruka Therapeutics Inc | 2024-09-30 | New Buy New Buy | +1.84% | 22.83 ($25.52) 29.62 | $12.60 | -50.63% | New holding | 375,330 | 375,330 | |
ENGN | enGene Holdings Inc | 2024-09-30 | Add Add | +0.33% | 5.26 ($7.44) 9.5 | $3.80 | -48.92% | Add 49.55% | 747,750 | 247,750 | |
ALMS | Alumis Inc | 2024-06-30 | New Buy New Buy | +8.16% | 13.3 ($13.3) 13.3 | $3.40 | -74.44% | New holding | 1,959,896 | 1,959,896 | |
ENGN | enGene Holdings Inc | 2024-06-30 | New Buy New Buy | +1.48% | 7.7 ($12.83) 16.9 | $3.80 | -70.38% | New holding | 500,000 | 500,000 | |
KALA | Kala Bio Inc | 2024-06-30 | New Buy New Buy | +0.98% | 4.6 ($6.61) 7.99 | $5.10 | -22.84% | New holding | 443,661 | 443,661 |
SR ONE CAPITAL MANAGEMENT, LP Total Holding History ($B)
SR ONE CAPITAL MANAGEMENT, LP's Asset Allocation
SR ONE CAPITAL MANAGEMENT, LP Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
SR ONE CAPITAL MANAGEMENT, LP's Hypothetical Growth since 2025-03-31
SR ONE CAPITAL MANAGEMENT, LP's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
SR ONE CAPITAL MANAGEMENT, LP's Holdings Heat Map
Size field:
SR ONE CAPITAL MANAGEMENT, LP's Holdings Bubble Chart
SR ONE CAPITAL MANAGEMENT, LP News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers